Announcement follows encouraging news from collaboration with French drugmaker Sanofi
GlaxoSmithKline has unveiled positive interim results from mid-stage trials of a Covid-19 vaccine it is developing with the Canadian biotech firm Medicago, a day after releasing strong data from its vaccine collaboration with the French drugmaker Sanofi.
The double dose of positive vaccine news gives GSK a boost at a time when its chief executive, Emma Walmsley, is under intense pressure from a new activist investor, the New York hedge fund Elliott Management, which took a sizeable stake in April.
